Wounds and InjuriesBurnsMohs SurgeryDiabetic Foot Ulcer MixedVenous Leg UlcerNon-healing WoundTrauma InjuryInjury and WoundsDegloving InjuriesPressure Ulcers, Bedsores, Decubitus Ulcer
Investigational drug(s) / intervention(s)
Various types of wound care treatments
Various types of wound care treatments: Treatments including, but not limited to:
* Hydrocolloid
* Foam
* Alginate
* Hydrogel
* Collagen
* Antimicrobial (e.g., silver, iodine)
* Film
* Composite
* Negative Pressure (NPWT)
* Amniotic-based
Study summary
The proposed registry Sponsor (Siddhey LLC) will collect data on various wound treatments in real life settings. Data collection will facilitate the analysis of the safety and efficacy of wound treatments.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria
1. Subject is male or female ≥18 years of age.
2. Subject has an ulcer (Diabetic foot ulcer, Venous stasis ulcer, etc.), injury (trauma, post -surgical, MOHS treatment), Burns injury, and/or other acute/chronic wounds.
3. Subject has clinical documentation of no visible wound improvement in the wound after 4 weeks of standard of care therapy.
4. Study wound is a minimum of 1 cm2 at Visit 1.
5. The subject is able and willing to follow the protocol requirements.
6. The subject has signed the informed consent form.
7. Subject has adequate circulation to the affected extremity. Note: This will be confirmed by vascular perfusion assessment performed prior to enrollment, if clinically indicated per Institutional standard of care.
Exclusion Criteria
1. Subject has a known life expectancy \< 1 year.
2. Subject has major uncontrolled medical disorders such as serious cardiovascular, renal, liver, or pulmonary disease, lupus, palliative care or sickle cell anemia.
3. Subject currently being treated for an active malignant disease or subjects with a history of malignancy within the wound.
4. Known contraindications to advance therapy tissues or products.
5. Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids \>10 mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the wound surface within one month prior to Visit 1.
6. Affected extremity requiring hyperbaric oxygen during the study or within 2 weeks of Visit 1.
7. Known HbA1c \>12%.
8. Subjects who are pregnant or breastfeeding.
Primary outcome measure(s)
Percentage wound area reduction over time while receiving study product using wound imaging device software or measurement scale — Up to 12 weeks Analysis will be based on product type (e.g., hydrocolloid, amniotic-based, etc.) and wound type (e.g., DFU, VLU, etc.)
Incidence and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events (AEs) related to wounds, and device-related adverse events (DRAEs) — Up to 12 weeks Note: Analysis will be based on product type (e.g., hydrocolloid, amniotic-based, etc.) and wound type (e.g., DFU, VLU, etc.)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.